DIRS.INFO The most relevant business & tech news

☆ Obesity drugs will be the largest pharamaceutical class ever, says Emily Field
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity drugs will be the largest pharamaceutical class ever, says Emily FieldEmily Field, Director and Lead Analyst of European Pharmaceuticals at Barclays, discusses weight-loss and GLP-1 drugs.

Persons: Emily, Emily Field Organizations: European Pharmaceuticals, Barclays

☆ These are the only 2 ETFs that made money every year for the past decade
▼ + stars: | 2024-02-19 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Two funds investing in defensive stocks are the only exchange-traded funds in the world that had a positive return every year over the past decade, CNBC Pro research has found. The two funds stood out among 8,300 equity ETFs worldwide screened by CNBC Pro using FactSet data. Over that period, the ETF more than doubled investors' money, with a cumulative total price gain of 118%. While the MSCI Healthcare index, valued in euros, dipped slightly into negative territory in 2016, 2020 and 2022, the Amundi ETF's total returns have remained positive because of the weakness in the pound sterling. However, Tabet also pointed out that the health-care sector, especially European pharma, tends to underperform in election years.

Persons: Joakim Tabet, Kepler, Tabet, Vincent Denoiseux, David Evans, Evans, Kepler Cheuvreux Organizations: CNBC, Healthcare UCITS, London Stock Exchange, TSX, Consumer Staples, CNBC Pro, Outlook Novo Nordisk, Novo Nordisk's, pharma, European pharma Locations: Canadian, Europe, Danish, Novo, U.S

☆ Obesity 'bolt-ons' likely to spur pharma M&A in 2024: Analyst
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity 'bolt-ons' likely to spur pharma M&A in 2024: AnalystEmily Field, director and head of European pharmaceuticals equity research at Barclays, says the industry is likely to see an uptick in mergers and acquisitions in 2024, especially with smaller deals in the obesity drugs space.

Persons: Emily Field Organizations: pharma, Barclays

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

In public, the company has announced its staggering growth with a steady cadence of news releases. But in classified American intelligence channels, there have been more concerning reports about the company. and other American spy agencies have issued warnings about G42’s work with large Chinese companies that U.S. officials consider security threats, including Huawei, the telecommunications giant that is under U.S. sanctions. U.S. officials fear G42 could be a conduit by which advanced American technology is siphoned to Chinese companies or the government. The intelligence reports have also warned that G42’s dealings with Chinese firms could be a pipeline to get the genetic data of millions of Americans and others into the hands of the Chinese government, according to two officials familiar with the reports.

Persons: Sheikh Tahnoon bin Zayed, Jake Sullivan Organizations: United Arab, White House, AstraZeneca, OpenAI, Huawei Locations: United Arab Emirates, China, Silicon, U.S

☆ Wegovy slashes risk of serious heart events: What this means for patients and insurers
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWegovy slashes risk of serious heart events: What this means for patients and insurersEmily Field, head of European Pharmaceutical Research at Barclays, joins 'Squawk Box' to discuss a new study that suggests that the weight-loss drug Wegovy reduces the risks of heart attacks, what these results mean for patients and insurers, and more.

Persons: Emily Field Organizations: European Pharmaceutical Research, Barclays

It also expects total revenue to increase by a mid single-digit percentage, compared with low-to-mid single-digit growth previously. For the third consecutive quarter, strong sales of AstraZeneca's blockbuster cancer treatments and healthy demand for its drugs in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy. The results add to a string of strong quarters for Britain's biggest company by market capitalisation - worth 159 billion pounds ($195 billion) - bolstered by a strong pipeline of drugs. It said that in the first nine months of 2023, nine medicines delivered more than $1 billion in revenue. Excluding sales of its COVID-19 products, third-quarter sales rose 12% to $2.96 billion in emerging markets on a constant currency basis.

Persons: Phil Noble, China's, Maggie Fick, Eva Mathews, Nivedita Bhattacharjee, Mark Potter Organizations: AstraZeneca, REUTERS, Britain's, Thomson Locations: Macclesfield, England, China, London, Swedish, Bengaluru

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race
▼ + stars: | 2023-08-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBarclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceEmily Field, Head of European Pharmaceutical Research at Barclays, discusses Novo Nordisk, Eli Lilly, and competition in the weight-loss/obesity drug space.

Persons: Eli Lilly, Emily Field Organizations: Barclays, Novo Nordisk, European Pharmaceutical Research

☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
▼ + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +3 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.

Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S

☆ This weight-loss drug maker's stock is up 20% this year — and Barclays sees it going higher
▼ + stars: | 2023-04-28 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Wegovy catapulted into the spotlight thanks to its success in weight loss and the endorsement by celebrities and social media influencers, including Tesla CEO Elon Musk. However, some investors are concerned that Novo's stock has already factored in this growth potential, as its shares have risen by 137% since the U.S. Food and Drug Administration approved the drug in June 2021. Novo's shares are also traded in New York Stock, London , and Frankfurt. NVO 5Y mountain According to Barclays' Field, the market for obesity treatment drugs could be worth as much as $200 billion within the next decade. "So does the weight loss that comes with taking Wegovy prevent you from having a heart attack or a stroke among those that have a higher risk?

A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection. "The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," he said. He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect. Bayer shares lag'HIGHLY ATTRACTIVE'In the United States, a different set of drug market rule changes are underway, with some of the highest-selling products set to see negotiated price discounts under the Inflation Reduction Act (IRA). Among the biggest drivers was the company's decision to prepare a U.S. launch of its next-generation stroke prevention drug asundexian on its own.

☆ Forget chips — UBS says to load up on this global sector instead
▼ + stars: | 2023-03-10 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

European equity investors should stay steer clear of semiconductor stocks and load up on banks this year, according to UBS' Head of European Equity Strategy Gerry Fowler. According to FactSet data, there were 24 banks in the Stoxx Europe 600 Banks index with a P/B ratio of less than 1. The index is accessible to investors through a number of ETFs, such as those from iShares (Ticker EXV1-DE) and Lyxor (Ticker BNK-FR). Cautious on chip stocks, pharma Fowler urged caution on semiconductor stocks — something of a hot sector this year — which he described as a "tactical decision." He noted that this year would see weak U.S. growth and a weak dollar, making pharma and household and personal products weak choices.

☆ Europe will lose out on medical innovation if draft EU reforms pass -Novo Nordisk CEO
▼ + stars: | 2023-03-02 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

LONDON, March 2 (Reuters) - Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape change, the CEO of Danish drugmaker Novo Nordisk (NOVOb.CO) warned on Thursday. It says drugs need to reach patients more quickly and in all European nations. Novo's Lars Jorgensen lamented that without changes to the current draft, his company would be forced to research, test and bring products in its pipeline to market in the United States and elsewhere, instead of in Europe. A lose, lose, lose," he said in an interview. The Commission's current draft was leaked in Brussels last month and will likely change even before debate in the European parliament and among governments.

☆ Pfizer in talks to buy cancer drugmaker Seagen - WSJ
▼ + stars: | 2023-02-27 | by ( ) www.reuters.com time to read: +2 min

Feb 27 (Reuters) - Pfizer Inc (PFE.N) is in early-stage talks to acquire cancer drugmaker Seagen Inc (SGEN.O) in a potential multi-billion dollar deal, the Wall Street Journal reported, after advanced discussions between Merck (MRK.N) and Seagen fell through last year. Seagen had a market capitalization of roughly $30 billion, as of Friday's close. Its shares have fallen nearly 10% since July, when the deal talks with Merck were first reported. Pfizer declined to comment on the WSJ report, while Seagen did not immediately respond to a Reuters request for comment. Merck, which bought ADC-maker Imago BioSciences for $1.35 billion in November, is unlikely to show renewed interest in Seagen, analysts said.

☆ Goldman Sachs closes $9.7 bln private-equity fund, largest since 2007
▼ + stars: | 2022-09-27 | by ( Saeed Azhar | ) www.reuters.com time to read: +2 min

FILE PHOTO: The Goldman Sachs company logo is on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 13, 2021. REUTERS/Brendan McDermid/File Photo/File PhotoNEW YORK, Sept 27 (Reuters) - Goldman Sachs Group Inc has closed a $9.7 billion private-equity fund, its largest since 2007, that seeks to invest in companies with an enterprise value of about $750 million to $2 billion, the bank said on Tuesday. The fund sits under the Wall Street giant's asset management arm and is known as "West Street Capital Partners VIII." Register now for FREE unlimited access to Reuters.com RegisterGoldman's money managers are not alone in raising PE funds. BlackRock Inc (BLK.N) has about $35 billion focused on PE strategies, and last year alone, it raised $3 billion to invest in PE secondary market deals.

Search resuls for: "European pharma"

16 mentions found